Compared with those in normal brain tissues, the mRNA and protein levels of UBE2C were elevated approximately 1-fold and 0.8-fold, respectively, in the brain tissues of glioma patients who were sensitive to TMZ but 5-fold and 2.2-fold, respectively, in patients with TMZ resistance (Figure 1A,B). The gene discussed is UBE2C; the disease is central nervous system cancer.